Skip to main content

Cellyan Biotechnology Co., Ltd

For the period ended Mar 31, 2026. Filed Aug 7, 2026.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2026 · Filed Aug 7, 2026

HKPD$1.45+6.6%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 20-F

(Mark one)

☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended March 31,2026

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to _________

OR

☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of event requiring this shell company report __________

Commission file number001-42468

CELLYAN BIOTECHNOLOGY CO., LTD

(Exact name of the Registrant as specified in its charter)

Not Applicable

(Translation of Registrant’s name into English)

Cayman Islands

(Jurisdiction of incorporation or organization)

Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong

(Address of principal executive offices)

Chenyu Liang, Chief Executive Officer

Tel:+852 2618-9289

Email: andy@cell-yan.com

Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong

(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)

Securities registered or to be registered pursuant to Section 12(b) of the Act:

Title of each classTrading SymbolName of each exchange on which registered
Class A Ordinary Shares, par value $0.001 per shareHKPDThe Nasdaq Stock Market LLC

Securities registered or to be registered pursuant to Section 12(g) of the Act:

None

(Title of Class)

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:

None

(Title of Class)

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report: As of March 31, 2026,16,349,986 Class A Ordinary Shares, par value $0.001 per share.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

☐ Yes☒ No

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

☐ Yes☒ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒ Yes☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

☒ Yes☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated filer ☐Accelerated filer ☐Non-accelerated filer ☒
Emerging Growth Company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.☐

†The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

US GAAP ☐International Financial Reporting Standards as issuedOther ☐
by the International Accounting Standards Board ☒

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.

☐ Item 17☐ Item 18

If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

☐ Yes☒ No

(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.

☐ Yes☐ No

Annual Report on Form 20-F

Year Ended March 31, 2026

TABLE OF CONTENTS

Page
PART I
Item 1.Identity of Directors, Senior Management and Advisers1
Item 2.Offer Statistics and Expected Timetable1
Item 3.Key Information1
3.A.[Reserved]1
3.B.Capitalization and Indebtedness1
3.C.Reasons for the Offer and Use of Proceeds1
3.D.Risk Factors1-34
Item 4.Information on the Company34
4.A.History and Development of the Company34-36
4.B.Business Overview37-51
4.C.Organizational Structure51
4.D.Property, Plants and Equipment51-53
Item 4A.Unresolved Staff Comments53
Item 5.Operating and Financial Review and Prospects53-54
5.A.Operating Results54-57
5.B.Liquidity and Capital Resources57-59
5.C.Research and Development, Patents and Licenses, etc.59
5.D.Trend Information59
5.E.Critical Accounting Estimates60-62
Item 6.Directors, Senior Management and Employees63
6.A.Directors and Senior Management63-65
6.B.Compensation65
6.C.Board Practices66-69
6.D.Employees69
6.E.Share Ownership69
6.F.Disclosure of a registrant’s action to recover erroneously awarded compensation69
Item 7.Major Shareholders and Related Party Transactions70
7.A.Major Shareholders70
7.B.Related Party Transactions71
7.C.Interests of Experts and Counsel71
Item 8.Financial Information71
8.A.Consolidated Statements and Other Financial Information71
8.B.Significant Changes72
Item 9.The Offer and Listing72
9.A.Offer and Listing Details72
9.B.Plan of Distribution72
9.C.Markets72
9.D.Selling Shareholders72
9.E.Dilution72
9.F.Expenses of the Issue72

i

Item 10.Additional Information72
10.A.Share Capital72
10.B.Memorandum and Articles of Association73
10.C.Material Contracts73
10.D.Exchange Controls73
10.E.Taxation74
10.F.Dividends and Paying Agents74
10.G.Statements by Experts74
10.H.Documents on Display74
10.I.Subsidiary Information74
Item 11.Quantitative and Qualitative Disclosures About Market Risk74
Item 12.Description of Securities Other Than Equity Securities75
12.A.Debt Securities75
12.B.Warrants and Rights75
12.C.Other Securities75
12.D.American Depositary Shares75
PART II
Item 13.Defaults, Dividend Arrearages and Delinquencies76
Item 14.Material Modifications to the Rights of Security Holders and Use of Proceeds76
Item 15.Controls and Procedures76
Item 16.[Reserved]77
16A.Audit Committee and Financial Expert77
16B.Code of Ethics77
16C.Principal Accountant Fees and Services78
16D.Exemptions from the Listing Standards for Audit Committees78
16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers78
16F.Change in Registrant’s Certifying Accountant78
16G.Corporate Governance79
16H.Mine Safety Disclosure79
16I.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections79
16J.Insider Trading Policies79
16K.Cybersecurity80
PART III
Item 17.Financial Statements81
Item 18.Financial Statements81
Item 19.Exhibits81

ii

CERTAIN INFORMATION

As used in this Annual Report on Form 20-F (the “Annual Report”), unless otherwise indicated or the context otherwise requires, references to:

●“API” are to application programming interface;
●“Cellyan Biotechnology” are to Cellyan Biotechnology Co., Ltd, a holding company incorporated in the Cayman Islands as an exempted company, formally known as Hong Kong Pharma Digital Technology Holdings Limited, or “Hong Kong Pharma”;
●“Chinese government” or “PRC government” are to the government of Mainland China for the purposes of this Annual Report only;
●“Class A Ordinary Share(s)” are to Cellyan Biotechnology’s Class A ordinary shares, par value $0.001 per share;
●“Class B Redeemable Ordinary Share(s)” are to Cellyan Biotechnology’s Class B redeemable ordinary shares, par value $0.001 per share;
●“HK Subsidiaries” are to Cellyan Biotechnology’s direct wholly-owned subsidiaries, Joint Cross Border Logistics Company Limited, and V-Alliance Technology Supplies Limited, each a Hong Kong corporation; each, an HK Subsidiary;
●“HK$,” “HK Dollars” or “Hong Kong dollar(s)” are to the legal currency of Hong Kong;
●“Hong Kong” and “Hong Kong SAR” are to the Hong Kong Special Administrative Region of the People’s Republic of China;
●“IFRS” are to the International Financial Reporting Standards, as issued by the International Accounting Standards Board;
●“Joint Cross Border” are to Joint Cross Border Logistics Company Limited, an HK Subsidiary;
●“V-Alliance” are to V-Alliance Technology Supplies Limited, an HK Subsidiary;
●“Mainland China” are to the Mainland China of the PRC, excluding Taiwan, the special administrative regions of Hong Kong and Macau for the purposes of this Annual Report only;
●“Ordinary Shares” are to our Class A Ordinary Shares and our Class B Ordinary Shares, collectively;
●“PRC” and “China” are to the People’s Republic of China, including the special administrative regions of Hong Kong and Macau for the purposes of this Annual Report only;
●“PRC laws and regulations” or “PRC laws” are to the laws and regulations of Mainland China for the purposes of this Annual Report only;
●“RMB” or “Renminbi” are to the legal currency of China;

iii

●“Share Split” are to a 1-for-10 forward split effected on October 24, 2024, of the Company’s Class A and Class B Redeemable Ordinary Shares, by way of a share subdivision of its issued and unissued shares, with each of its issued and unissued shares subdivided into ten (10) shares. Immediately after the Share Split, the number of issued and outstanding shares of Cellyan Biotechnology increased from 1,000,000 to 10,000,000 shares, comprising (i) 9,501,000 Class A Ordinary Shares issued and outstanding, par value $0.001 each and (ii) 499,000 Class B Redeemable Ordinary Shares issued and outstanding, par value $0.001 each. All share and per share data set forth in this Annual Report have been retroactively adjusted to reflect the Share Split.
●“Selling Shareholders” are to the nineteen (19) investors who engaged in the March 2026 Private Placement, including Jiamei Qin, Yun Zhou, Yawen Zhang, Xiuhua Wang, Shunzeng Chen, Junqing Wang, Chunxia Wang, Huanyin Wang, Guojun Liu, Yundie Chi, Guorui Liu, Fuping Lin, Liuqin Bao, Xuanrui Chi, Xincun Li, Jindong Sun, Xiangyang Xu, Fengjun Xue and Xiangdie Liu.
●“U.S. dollars,” “dollars,” “USD” or “$” are to the legal currency of the United States; and
●“we,” “us,” “the Company,” “our” or “our company” are to the combined business of Cellyan Biotechnology Co., Ltd., an exempted company incorporated in Cayman Islands, and its consolidated subsidiaries.

This Annual Report contains translations of certain HK dollar amounts into U.S. dollar amounts solely for the convenience of the reader. These translations from Hong Kong dollars into U.S. dollars are determined as of a specific date or for a specific period. Changes in the exchange rate will affect the amount of our obligations and the value of our assets in terms of U.S. dollars which may result in an increase or decrease in the amount of our obligations (expressed in dollars) and the value of our assets. No representation is made that HK$ or $ amount represents or could have been, or could be converted, realized or settled into $ or HK$, as the case may be, at any particular rate, or at all.

Numerical figures included in this Annual Report have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.

Our fiscal year end is March 31. References to a particular “fiscal year” are to our fiscal year ended March 31 of that calendar year. Our consolidated financial statements have been prepared in accordance with IFRS.

For the sake of clarity, this report follows the English naming convention of given name followed by family name, regardless of whether an individual’s name is Chinese or English. For example, the name of our Chief Executive Officer is presented here as “Chenyu Liang,” even though Mr. Liang’s name in Chinese is presented as “Liang Chenyu.”

This Annual Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, you are cautioned not to give undue weight to this information.

We have proprietary rights to trademarks used in this Annual Report that are important to our business. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report are without the®,™ and other similar symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names.

This Annual Report may contain additional trademarks, service marks and trade names of others. All trademarks, service marks and trade names appearing in this Annual Report are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies’ trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other person.

iv

FORWARD-LOOKING STATEMENTS

This Annual Report contains many statements that are “forward-looking” and uses forward-looking terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “future,” “intend,” “may,” “ought to,” “plan,” “possible,” “potentially,” “predicts,” “project,” “should,” “will,” “would,” negatives of such terms or other similar statements. You should not place undue reliance on any forward-looking statement due to its inherent risk and uncertainties, both general and specific. Although we believe the assumptions on which the forward-looking statements are based are reasonable and within the bounds of our knowledge of our business and operations as of the date of this Annual Report, any or all of those assumptions could prove to be inaccurate. As a result, the forward-looking statements based on those assumptions could also be incorrect. The forward-looking statements in this Annual Report include, without limitation, statements relating to:

●our goals and strategies;
●our future business development, financial condition and results of operations;
●expected changes in our revenue, costs or expenditure;
●our expectations regarding demand for and market acceptance of our products and services;
●competition in our industry; and
●government policies and regulations relating to our industry.

The forward-looking statements included in this Annual Report are subject to known and unknown risks, uncertainties and assumptions about our businesses and business environments. These statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual results of our operations may differ materially from information contained in the forward-looking statements as a result of risk factors, some of which are described under the headings “Risk Factors,” “Operating and Financial Review and Prospects,” “Information on our Company” and elsewhere in this Annual Report. Such risks and uncertainties are not exhaustive. Other sections of this Annual Report include additional factors which could adversely impact our business and financial performance. The forward-looking statements contained in this Annual Report speak only as of the date of this Annual Report or, if obtained from third-party studies or reports, the date of the corresponding study or report, and are expressly qualified in their entirety by the cautionary statements in this Annual Report. Since we operate in an emerging and evolving environment and new risk factors and uncertainties emerge from time to time, you should not rely upon forward-looking statements as predictions of future events. Except as otherwise required by the securities laws of the United States, we undertake no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events.

v

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.